Key result
Switching to a combination therapy of high-dose ARB, CCB, and hydrochlorothiazide significantly reduced systolic blood pressure from 142 mmHg to 125 mmHg and increased target BP achievement to 72% at 3 months.
Why the study?
Does switching to a triple combination of high-dose ARB, CCB, and HCTZ improve blood pressure control in hypertensive patients inadequately controlled on prior therapies?
Observational (n=32)
Open-label
Does switching to a triple combination of high-dose ARB, CCB, and HCTZ improve blood pressure control in hypertensive patients inadequately controlled on prior therapies?
Answers are grounded in this paper and cite their sources.
Switching to a triple combination of high-dose ARB, CCB, and HCTZ significantly improves blood pressure control in hypertensive patients inadequately controlled on prior dual or lower-dose triple therapies.
BACKGROUND: Many patients continue to have high blood pressure (BP) even after treatment with high-dose (H)-angiotensin II type 1 receptor blocker (ARB)/calcium channel blocker (CCB) or middle-dose (M)-ARB/CCB/hydrochlorothiazide (HCTZ). METHODS: Thirty-two hypertensive patients who had the use of H-ARB/CCB or M-ARB/CCB/HCTZ were enrolled in this study. We applied a changeover with a switch to H-ARB (telmisartan 80 mg/day)/CCB (amlodipine 5 mg/day or nifedipine CR 40 mg/day)/HCTZ (12.5 mg/day). RESULTS: Systolic BP (SBP) and diastolic BP (DBP) were significantly decreased in all patients and in the H-ARB/CCB and M-ARB/CCB/HCTZ groups after 3 months. Percentage (%) of patients who reached the target BP after 3 months (72%) in all patients was significantly higher than that at 0 months (19%). There were no serious adverse effects in any of the patients. CONCLUSIONS: Combination therapy with H-ARB/CCB/HCTZ was associated with a significant reduction of BP.
No takes yet. Share an insight, caveat, or question.
Shiga et al. (2016) conducted an observational in Hypertension (n=32). High-dose ARB (telmisartan), CCB, and hydrochlorothiazide vs. Baseline (previous therapy with H-ARB/CCB or M-ARB/CCB/HCTZ) was evaluated on Systolic blood pressure (p=<0.05). Switching to a combination therapy of high-dose ARB, CCB, and hydrochlorothiazide significantly reduced systolic blood pressure from 142 mmHg to 125 mmHg and increased target BP achievement to 72% at 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: